{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-129824","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.639439+00:00","generated_at":"2026-06-07T06:21:58.134308+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theravance settles YUPELRI patent litigation with Accord; generic entry allowed no earlier than April 23, 2039","bullets":["Settlement Agreement with Accord resolves Hatch-Waxman litigation over YUPELRI inhalation solution.","Accord granted royalty-free license to market generic YUPELRI on or after April 23, 2039, subject to customary exceptions.","Settlement subject to review by U.S. Department of Justice and Federal Trade Commission.","Patent litigation continues against five other ANDA filers: Cipla, Eugia, Lupin, Mankind, and Orbicular."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-129824","json":"https://secwatch.observer/filing/0001104659-23-129824.json","markdown":"https://secwatch.observer/filing/0001104659-23-129824.md","text":"https://secwatch.observer/filing/0001104659-23-129824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923129824/0001104659-23-129824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923129824/tm2333786d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:21:58.134308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}